Who is sponsoring NCT03715127?

NCT03715127 is sponsored by University of Zurich.

What drugs are being tested in NCT03715127?

Interventions in NCT03715127: Psilocybine oral capsule, Placebo oral capsule.

What condition does NCT03715127 study?

NCT03715127 studies Depressive Disorder, Major.

Is NCT03715127 still recruiting?

NCT03715127 is currently completed. Last updated 29 April 2022.

Last reviewed 2022-04-29 · How we verify

NCT03715127

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical, Neurocognitive, and Emotional Effects of Psilocybin in Depressed Patients - Proof of Concept

Completed Phase 2 Last updated 29 April 2022

What this trial tests

Phase 2 trial testing Psilocybine oral capsule in Depressive Disorder, Major in 55 participants. Completed in 12 April 2022.

Timeline

11 March 2019

Primary endpoint
12 October 2021

12 April 2022

Quick facts

Lead sponsor	University of Zurich
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	55
Start date	11 March 2019
Primary completion	12 October 2021
Estimated completion	12 April 2022
Sites	1 location across Switzerland

Drugs / interventions tested

Psilocybine oral capsule
Placebo oral capsule

Conditions studied

Depressive Disorder, Major — all drugs for Depressive Disorder, Major →

Sponsor

University of Zurich

Who can join

Adults 18 to 60, any sex, with Depressive Disorder, Major. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Effects of serotonin 2A/1A receptor stimulation by psilocybin on mood and emotion processing in major depressive disorder: a randomized double-blind placebo-controlled study

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial.
von Rotz R, Schindowski EM, Jungwirth J, Schuldt A, et al · · 2023 · cited 188× · PMID 36636296 · DOI 10.1016/j.eclinm.2022.101809
The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de-risk trial programmes of novel agents.
Correll CU, Solmi M, Cortese S, Fava M, et al · · 2023 · cited 90× · PMID 36640403 · DOI 10.1002/wps.21056
Psychedelic Therapy's Transdiagnostic Effects: A Research Domain Criteria (RDoC) Perspective.
Kelly JR, Gillan CM, Prenderville J, Kelly C, et al · · 2021 · cited 36× · PMID 34975593 · DOI 10.3389/fpsyt.2021.800072
Clinical specificity profile for novel rapid acting antidepressant drugs.
Scala M, Fanelli G, De Ronchi D, Serretti A, et al · · 2023 · cited 33× · PMID 37381161 · DOI 10.1097/yic.0000000000000488
Rethinking Therapeutic Strategies for Anorexia Nervosa: Insights From Psychedelic Medicine and Animal Models.
Foldi CJ, Liknaitzky P, Williams M, Oldfield BJ. · · 2020 · cited 33× · PMID 32116500 · DOI 10.3389/fnins.2020.00043
Novel Antidepressants in the Pipeline (Phase II and III): A Systematic Review of the US Clinical Trials Registry.
Sakurai H, Yonezawa K, Tani H, Mimura M, et al · · 2022 · cited 21× · PMID 35045580 · DOI 10.1055/a-1714-9097
What is the clinical evidence on psilocybin for the treatment of psychiatric disorders? A systematic review.
Castro Santos H, Gama Marques J. · · 2021 · cited 20× · PMID 33884324 · DOI 10.1097/j.pbj.0000000000000128
The Use of Psychedelics in the Treatment of Medical Conditions: An Analysis of Currently Registered Psychedelics Studies in the American Drug Trial Registry.
Kurtz JS, Patel NA, Gendreau JL, Yang C, et al · · 2022 · cited 19× · PMID 36259015 · DOI 10.7759/cureus.29167

Verify or expand the search:

Other recruiting trials for Depressive Disorder, Major

Currently open trials in the same condition.

NCT07227454 — A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder · Phase 3 · recruiting
NCT07258485 — A Study to Evaluate Sleep Electroencephalogram (EEG) Features (Brain Activity While Sleeping) in Participants With Major · recruiting
NCT07059234 — The Motor Activity - Subjective Energy (MASE) Project · NA · recruiting
NCT06982820 — Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia · NA · recruiting
NCT05553353 — Dosing rTMS for Depression Post-SCI · NA · recruiting

Other University of Zurich trials

Trials by the same sponsor.

NCT07485699 — Soy Processing and Food Allergy · NA · not yet recruiting
NCT07516912 — Evaluation of Free STI Testing Pilot Projects in Lucerne and Zurich, Switzerland · not yet recruiting
NCT07473115 — Individualized Analgesia in the Intensive Care Unit With a New Pain Assessment Bundle and Protocolized Analgesia Adjustm · not yet recruiting
NCT07524023 — Emotional-distress-based Integrated Care Programme in Patients With Stable COPD · NA · recruiting
NCT06481982 — Value of Advanced MRI Techniques in the Assessment of Endometriosis · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03715127 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Zurich
Last refreshed: 29 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03715127.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing